Clinical trial · Interventional
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients
NCT02946671CI-TRIAL-00043868completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the safety of preoperative combination therapy with KW-0761 (anti-CCR4) and ONO-4538 (anti-PD-1). To assess the behavior of immune cells in peripheral blood and tumor.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Oral Cancer | Malignant Lip and Oral Cavity Neoplasm | CURATED_BROADER | 0.80 |
| Renal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mogamulizumab | Biological | Mogamulizumab | ALIAS |
| Nivolumab | Biological | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort 1
- description
- KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
- interventionNames
- Biological: Mogamulizumab
- Biological: Nivolumab
- type
- EXPERIMENTAL
- label
- Cohort 2
- description
- KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
- interventionNames
- Biological: Mogamulizumab
- Biological: Nivolumab
- type
- EXPERIMENTAL
- label
- Cohort 3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who enable to have standard operation * Patients who refuse standard preoperative chemotherapy and are diagnosed with following cancers; gastric adenocarcinoma, esophageal squamous cell carcinoma, non-small-cell lung carcinoma, renal cell carcinoma or oral squamous cell carcinoma * Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patients with no serious disorder of major organs (born marrow, heart, lung, liver and kidney) * Patients with written informed consent * Patients who have measurable target lesion * Patients who are enable to undergo biopsy for sampling tumor tissue Exclusion Criteria: * Known or previous autoimmune disease * Known or suspected interstitial lung disease (ILD) * Patients with history of serious anaphylaxis induced by antibody preparation * Uncontrollable hypertension * Uncontrollable endocrine disease * Patients who have active inflammatory bowel disease or other serious GI chronic conditions associated with diarrhea * Uncontrollable diabetes * Prior therapy with sustained anticancer agents, radiotherapy or surgery for primary disease * Pregnant or lactating females, female and male patients who cannot agree to practice the adequate birth control after the consent during the study * Known or suspected infection or inflammatory disease * Prior therapy with hematopoietic stem cell transplantation * Known or suspected central nervous system (CNS) involvement
References
Publications (1)
- DERIVEDJinushi K, Saito T, Kurose K, Suzuki S, Kojima T, Takahara T, Makino T, Ogawa T, Nishikawa H, Kakimi K, Iida S, Nakajima J, Doki Y, Oka M, Ueda R, Wada H. Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors. J Immunother Cancer. 2025 Apr 2;13(4):e010634. doi: 10.1136/jitc-2024-010634. PMID 40180420